Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
LumiraDx Limited LMDX
$0.53
-$0.02 (-4.52%)
На 18:04, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
253680635.00000000
-
week52high
4.71
-
week52low
0.45
-
Revenue
254476000
-
P/E TTM
0
-
Beta
0.91051300
-
EPS
-1.51000000
-
Last Dividend
0.00000000
-
Next Earnings Date
10 мая 2023 г. в 04:00
Описание компании
LumiraDx Limited operates as a point of care diagnostics company. The company focuses on transforming community-based healthcare by providing critical diagnostic information to healthcare providers. It manufactures and commercializes a diagnostic platform that supports various tests with lab comparable performance at the point of care. The company has approximately 30 tests on the market and in development covering infectious diseases, cardiovascular diseases, diabetes, and coagulation disorders, as well as a portfolio of COVID-19 testing solutions from the lab to point of need. Its diagnostic testing solutions are deployed by governments and healthcare institutions across laboratories, urgent care, physician offices, pharmacies, schools, and workplaces to screen, diagnose, and monitor wellness, as well as disease. The company was founded in 2014 and is headquartered in London, the United Kingdom.
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
LumiraDx Limited (LMDX) Q3 2022 Earnings Call Transcript
Seeking Alpha
12 ноя 2022 г. в 15:13
LumiraDx Limited (NASDAQ:LMDX ) Q3 2022 Results Conference Call November 9, 2022 8:00 AM ET Company Participants Colleen McMillen - Vice President, Communications Ron Zwanziger - Chairman and CEO Dorian LeBlanc - Chief Financial Officer Conference Call Participants Jeffrey Cohen - Ladenburg Tallman Andrew Cooper - Raymond James Operator Good day and thank you for standing by. Thank you for joining LumiraDx Third Quarter 2022 Earnings Conference Call.
LumiraDx Limited (LMDX) Reports Q3 Loss, Tops Revenue Estimates
Zacks Investment Research
09 ноя 2022 г. в 09:47
LumiraDx Limited (LMDX) delivered earnings and revenue surprises of -56.67% and 46.15%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
LumiraDx to Announce Third Quarter Financial Results and Host Quarterly Conference Call on November 9
GlobeNewsWire
02 ноя 2022 г. в 07:23
LONDON, Nov. 02, 2022 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care (POC) diagnostics company, announced it will release its third quarter financial results on Wednesday, November 9th, 2022. On the day of the release, LumiraDx will host a conference call and webcast at 8:00 AM Eastern Time to review the financial results and business highlights.
LumiraDx Partners with British In Vitro Diagnostics Association to Report on the Role of Rapid Diagnostics in Tackling Antimicrobial Resistance
GlobeNewsWire
22 сент 2022 г. в 04:12
Testing Times Report reflects expert opinion that “Supporting more widespread use of rapid diagnostic technology should be a central aim of efforts to tackle the next hidden pandemic” Testing Times Report reflects expert opinion that “Supporting more widespread use of rapid diagnostic technology should be a central aim of efforts to tackle the next hidden pandemic”
LumiraDx Limited's (LMDX) CEO Ron Zwanziger on Q2 2022 Results - Earnings Call Transcript
Seeking Alpha
18 авг 2022 г. в 11:45
LumiraDx Limited (NASDAQ:LMDX ) Q2 2022 Earnings Conference Call August 18, 2022 8:00 AM ET Company Participants Colleen McMillen - Vice President, Communications Ron Zwanziger - Chairman and CEO Dorian LeBlanc - Chief Financial Officer Pooja Pathak - Chief Product Officer Conference Call Participants Vijay Kumar - Evercore ISI Jeffrey Cohen - Ladenburg Mark Massaro - BTIG Operator Good day. And welcome to the LumiraDx Second Quarter 2022 Earnings Call.